Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.
Kedhi E, Berta B, Roleder T, Hermanides RS, Fabris E, IJsselmuiden AJJ, Kauer F, Alfonso F, von Birgelen C, Escaned J, Camaro C, Kennedy MW, Pereira B, Magro M, Nef H, Reith S, Al Nooryani A, Rivero F, Malinowski K, De Luca G, Garcia Garcia H, Granada JF, Wojakowski W. Kedhi E, et al. Among authors: pereira b. Eur Heart J. 2021 Dec 1;42(45):4671-4679. doi: 10.1093/eurheartj/ehab433. Eur Heart J. 2021. PMID: 34345911 Free article. Clinical Trial.
Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
Hommels TM, Hermanides RS, Rasoul S, Berta B, IJsselmuiden AJJ, Jessurun GAJ, Benit E, Pereira B, De Luca G, Kedhi E. Hommels TM, et al. Among authors: pereira b. Cardiovasc Diabetol. 2019 Mar 9;18(1):25. doi: 10.1186/s12933-019-0827-z. Cardiovasc Diabetol. 2019. PMID: 30851731 Free PMC article.
The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study.
Hommels TM, Hermanides RS, Rasoul S, Berta B, IJsselmuiden AJJ, Jessurun GAJ, Benit E, Pereira B, De Luca G, Kedhi E. Hommels TM, et al. Among authors: pereira b. Neth Heart J. 2019 Nov;27(11):541-549. doi: 10.1007/s12471-019-1293-7. Neth Heart J. 2019. PMID: 31197750 Free PMC article.
Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT-FFR Trial.
Fabris E, Berta B, Roleder T, Hermanides RS, IJsselmuiden AJJ, Kauer F, Alfonso F, von Birgelen C, Escaned J, Camaro C, Kennedy MW, Pereira B, Magro M, Nef H, Reith S, Roleder-Dylewska M, Gasior P, Malinowski K, De Luca G, Garcia-Garcia HM, Granada JF, Wojakowski W, Kedhi E. Fabris E, et al. Among authors: pereira b. Circ Cardiovasc Interv. 2022 May;15(5):e011728. doi: 10.1161/CIRCINTERVENTIONS.121.011728. Epub 2022 Apr 29. Circ Cardiovasc Interv. 2022. PMID: 35485232 Free article.
Long-term outcomes of patients with normal fractional flow reserve and thin-cap fibroatheroma.
Fabris E, Berta B, Hommels T, Roleder T, Hermanides RS, Rivero F, von Birgelen C, Escaned J, Camaro C, Kennedy MW, Pereira B, Magro M, Nef H, Reith S, Roleder-Dylewska M, Gasior P, Malinowski KP, De Luca G, Garcia-Garcia HM, Granada JF, Wojakowski W, Kedhi E. Fabris E, et al. Among authors: pereira b. EuroIntervention. 2023 Feb 6;18(13):e1099-e1107. doi: 10.4244/EIJ-D-22-00306. EuroIntervention. 2023. PMID: 36170036 Free PMC article. Clinical Trial.
Morphological characteristics of lesions with thin cap fibroatheroma-a substudy from the COMBINE (OCT-FFR) trial.
Roleder-Dylewska M, Gasior P, Hommels TM, Roleder T, Berta B, Ang HY, Ng JCK, Hermanides RS, Fabris E, IJsselmuiden AJJ, Kauer F, Alfonso F, von Birgelen C, Escaned J, Camaro C, Kennedy MW, Pereira B, Magro M, Nef H, Reith S, Malinowski K, De Luca G, Garcia Garcia HM, Granada JF, Wojakowski W, Kedhi E. Roleder-Dylewska M, et al. Among authors: pereira b. Eur Heart J Cardiovasc Imaging. 2023 Apr 24;24(5):687-693. doi: 10.1093/ehjci/jeac218. Eur Heart J Cardiovasc Imaging. 2023. PMID: 36342269
Rationale and design of amphilimus sirolimus-eluting stents versus zotarolimus-eluting stents in all-comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial.
Rozemeijer R, Stein M, Frambach P, Voskuil M, Kraaijeveld AO, Rodríguez-Olivares R, Timmers L, Pereira B, Rittersma SZ, Agostoni P, Doevendans PA, Stella PR. Rozemeijer R, et al. Among authors: pereira b. Catheter Cardiovasc Interv. 2018 Feb 15;91(3):410-416. doi: 10.1002/ccd.27142. Epub 2017 May 22. Catheter Cardiovasc Interv. 2018. PMID: 28544782
3-Year Clinical Outcomes After Implantation of Permanent-Polymer Versus Polymer-Free Stent: ReCre8 Landmark Analysis.
van Hemert ND, Voskuil M, Rozemeijer R, Stein M, Frambach P, Pereira B, Rittersma SZ, Kraaijeveld AO, Leenders GEH, Timmers L, van der Harst P, Agostoni P, Stella PR; ReCre8 Study Investigators. van Hemert ND, et al. Among authors: pereira b. JACC Cardiovasc Interv. 2021 Nov 22;14(22):2477-2486. doi: 10.1016/j.jcin.2021.08.078. JACC Cardiovasc Interv. 2021. PMID: 34794654 Free article. Clinical Trial.
Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; ReCre8 Study Investigators. Rozemeijer R, et al. Among authors: pereira b. Circulation. 2019 Jan 2;139(1):67-77. doi: 10.1161/CIRCULATIONAHA.118.037707. Circulation. 2019. PMID: 30586704 Clinical Trial.
2,284 results